Literature DB >> 28666780

Impact of moving to a new hospital build, with a high proportion of single rooms, on healthcare-associated infections and outbreaks.

E S R Darley1, J Vasant2, J Leeming2, F Hammond3, S Matthews3, M Albur2, R Reynolds2.   

Abstract

Clostridium difficile infection, meticillin-sensitive Staphylococcus aureus (MSSA) and Escherichia coli bacteraemia rates, and bed-days lost during norovirus outbreaks at North Bristol NHS Trust were analysed over a five-year period to determine whether moving to a new-build hospital with 75% single rooms reduced healthcare-associated infection rates. C. difficile, MSSA bacteraemia and E. coli bacteraemia showed no change in the rate of decline after the move. Bed-days lost due to norovirus were significantly lower after the move. Increased availability of single rooms had an impact on the transmission of highly contagious norovirus infection, dispersed via the airborne route, in contrast to bacterial infections, which may originate from patient's own colonizing flora and are not widely dispersed through airborne spread.
Copyright © 2017 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Clostridium difficile; Isolation; New-build; Norovirus; Single rooms

Mesh:

Year:  2017        PMID: 28666780     DOI: 10.1016/j.jhin.2017.06.027

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  2 in total

1.  Relocating a pediatric hospital: Does antimicrobial resistance change?

Authors:  Annika Schönfeld; Rudolf Ascherl; Stefanie Petzold-Quinque; Norman Lippmann; Arne C Rodloff; Wieland Kiess
Journal:  BMC Res Notes       Date:  2020-05-13

2.  Association between intrahospital transfer and hospital-acquired infection in the elderly: a retrospective case-control study in a UK hospital network.

Authors:  Emanuela Estera Boncea; Paul Expert; Kate Honeyford; Anne Kinderlerer; Colin Mitchell; Graham S Cooke; Luca Mercuri; Céire E Costelloe
Journal:  BMJ Qual Saf       Date:  2021-01-25       Impact factor: 7.035

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.